Search company, investor...

ProCertus BioPharm

Founded Year



Dead | Dead

Total Raised


About ProCertus BioPharm

ProCertus BioPharm develops and commercializes pharmaceutical products that prevent the common side effects of cancer therapy.

Headquarters Location

505 South Rosa Road Suite 175 B

Madison, Wisconsin, 53719,

United States


Missing: ProCertus BioPharm's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ProCertus BioPharm's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing ProCertus BioPharm

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ProCertus BioPharm is included in 1 Expert Collection, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

ProCertus BioPharm Patents

ProCertus BioPharm has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics



Radiation therapy, Medical physics, Transcription factors, Human hair, Cancer treatments


Application Date


Grant Date


Related Topics

Radiation therapy, Medical physics, Transcription factors, Human hair, Cancer treatments



Latest ProCertus BioPharm News

Radiodermatitis - Pipeline Review, H1 2016 Featuring ProCertus BioPharm, Reata Pharmaceuticals, SK Chemicals & Vida Therapeutics - Research and Markets

Jun 15, 2016

Radiodermatitis - Pipeline Review, H1 2016 Featuring ProCertus BioPharm, Reata Pharmaceuticals, SK Chemicals & Vida Therapeutics - Research and Markets June 15, 2016 01:07 PM Eastern Daylight Time DUBLIN--( BUSINESS WIRE )--Research and Markets has announced the addition of the "Radiodermatitis - Pipeline Review, H1 2016" report to their offering. This report provides comprehensive information on the therapeutic development for Radiodermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiodermatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered:

ProCertus BioPharm Frequently Asked Questions (FAQ)

  • When was ProCertus BioPharm founded?

    ProCertus BioPharm was founded in 1997.

  • Where is ProCertus BioPharm's headquarters?

    ProCertus BioPharm's headquarters is located at 505 South Rosa Road, Madison.

  • What is ProCertus BioPharm's latest funding round?

    ProCertus BioPharm's latest funding round is Dead.

  • How much did ProCertus BioPharm raise?

    ProCertus BioPharm raised a total of $6.1M.

  • Who are the investors of ProCertus BioPharm?

    Investors of ProCertus BioPharm include Novartis Venture Funds, Venture Investors, Wisconsin Alumni Research Foundation and Venturenvestors Early Stage Fund.

  • Who are ProCertus BioPharm's competitors?

    Competitors of ProCertus BioPharm include Sierra Oncology, DNAtriX, Endocyte, GenVec, Cebix and 9 more.

Compare ProCertus BioPharm to Competitors

American Stem Cell

ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.

Alethia BioTherapeutics

Alethia BioTherapeutics is a biotechnology company that develops monoclonal antibody therapeutics to clinically relevant targets identified using its STAR discovery technology.


Spaltudaq Corporation, a privately-held biotechnology company based in Seattle, is focused on developing therapeutic antibodies for the treatment of inflammation, infectious disease and cancer. Our technology harnesses the power of the human immune system to identify tumor-specific or pathogen-specific monoclonal antibodies from human tissue samples.

Arisyn Therapeutics

Arisyn Therapeutics Inc. is a biotechnology company focused on the development of first in class inhibitors of infectious disease and cancer. Arisyn possesses a portfolio of small molecule compounds that will be developed to treat Human Immunodeficiency Virus-Type 1 (HIV-1), Human Immunodeficiency Virus-Type 2 (HIV-2), Human T-Lymphotropic Virus-Type 1 (HTLV-1), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Herpes Simplex Virus-Type 2 (HSV-2). Arisyn will perform all necessary studies required to develop these therapeutic agents through Phase 1 and Phase 2 human clinical trials.

Limerick BioPharma

Limerick BioPharma is developing compounds that per the company when used adjunctively with both marketed and investigational drugs improve drug side effect profiles and clinical outcomes. By activating cellular transport pumps to redistribute drugs away from organs and tissues where they have adverse effects, the company's compounds aim to minimize toxic side effects at non-targeted vulnerable organs and tissues while maintaining or enhancing a drug's desired effects. Per the company, Limerick's pipeline molecules are applicable to a broad range of therapeutic drug classes including immunosuppressants, opioids, immunomodulators, selective estrogens receptor modulators, and psychotropics. In the monotherapy setting, Limerick is developing novel compounds that target the treatment of metabolic diseases such as hypercholesteremia and hyperglycemia via a mechanism related to reverse cholesterol transport.

Can-Fite Biopharma

Can-Fite is an Israeli science-based biopharmaceutical company with the mission to develop treatments for autoimmune diseases and cancer. The company's drugs which piggyback on a natural mechanism, are small molecules, orally administered, induce specific activity towards their target pathological cells and demonstrated an excellent safety profile in human clinical studies.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.